{"classes":[{"categories":[{"measurements":[{"comment":"Not Applicable - not all participants had an event at time of analysis, max time censored","groupId":"OG000","lowerLimit":"3.7","upperLimit":"NA","value":"13.9"},{"comment":"Not Applicable - not all participants had an event at time of analysis, max time censored","groupId":"OG001","lowerLimit":"2.5","upperLimit":"NA","value":"16.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"165"}],"units":"Participants"}],"description":"Time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who achieve a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) \\>=24 weeks","dispersionType":"Full Range","groups":[{"description":"Fulvestrant 250 mg Intramuscular Injection every 28 days","id":"OG000","title":"Fulvestrant 250 mg"},{"description":"Fulvestrant 500 mg Intramuscular Injection every 28 days plus 500 mg on day 14","id":"OG001","title":"Fulvestrant 500 mg"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments carried out every 12 weeks (+/- 2 weeks) from randomisation for study duration (48 months)","title":"Duration of Clinical Benefit (DoCB)","type":"SECONDARY","unitOfMeasure":"Time (in months)"}